Examining the costs and cost-effectiveness of novel TB regimens

Exploring the cost-effectiveness of the introduction of new TB drugs regimens, including the corresponding costs of drug-susceptability testing to prevent resistance.

LSHTM lead investigator: Anna Vassall
LSHTM staff: Gabriela Gomez
Funding: TB Alliance
Collaborators: Amsterdam Insitute for Global Health and Development
Brazil, Bangladesh, South Africa, Tanzania